Aforbes Dosage/Direction for Use

Adults: For both hypertension and angina, the usual initial dose is 5 mg amlodipine (Aforbes) once daily which may be increased to a maximum dose of 10 mg depending on the individual patient's response and severity.
No dose adjustment of amlodipine (Aforbes) is required upon concomitant administration of thiazide diuretics, beta-blockers and angiotensin-converting enzyme inhibitors.
In hypertensive patients, amlodipine (Aforbes) has been used in combination with a thiazide diuretic, alpha-blocker, beta-blocker, or an angiotensin-converting enzyme inhibitor. For angina, amlodipine (Aforbes) may be used as monotherapy or in combination with other anti-anginal medicinal products in patients with angina that is refractory to nitrates and/or to adequate doses of beta-blockers.
Special populations: Elderly patients: Amlodipine (Aforbes) used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care.
Patients with hepatic impairment: Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see Precautions). The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.
Patients with renal impairment: Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Amlodipine is not dialyzable.
Pediatric population: Children and adolescents with hypertension from 6 years to 17 years of age. The recommended antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily may not have been studied in pediatric patients.
Children under 6 years old: No data are available.